NASDAQ:GANX

Gain Therapeutics Stock Forecast, Price & News

$13.20
-0.80 (-5.71 %)
(As of 04/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.00
Now: $13.20
$14.00
50-Day Range N/A
52-Week Range
$11.00
Now: $13.20
$17.93
Volume62,113 shs
Average Volume171,225 shs
Market Capitalization$149.57 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Gain Therapeutics, Inc., a development stage biotechnology company, develops novel therapeutics to treat rare genetic and neurological disorders caused by protein misfolding in Switzerland and Spain. The company through its in-licensed proprietary Site-Directed Enzyme Enhancement Therapy platform, discovers novel allosteric sites on misfolded proteins, identifies proprietary binding sites, and restores protein folding. It has a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GANX
CUSIPN/A
CIKN/A
Phone301-500-1556
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$149.57 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

259th out of 2,019 stocks

Biotechnology Industry

20th out of 145 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$13.20
-0.80 (-5.71 %)
(As of 04/13/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GANX News and Ratings via Email

Sign-up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Gain Therapeutics (NASDAQ:GANX) Frequently Asked Questions

Is Gain Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Gain Therapeutics stock.
View analyst ratings for Gain Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Gain Therapeutics?

Wall Street analysts have given Gain Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gain Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GANX?

2 Wall Street analysts have issued 12 month target prices for Gain Therapeutics' stock. Their forecasts range from $30.00 to $30.00. On average, they anticipate Gain Therapeutics' stock price to reach $30.00 in the next twelve months. This suggests a possible upside of 127.3% from the stock's current price.
View analysts' price targets for Gain Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Gain Therapeutics' key executives?

Gain Therapeutics' management team includes the following people:
  • Dr. Khalid Islam, Founder & Chairman (Age 66)
  • Mr. Eric I. Richman M.B.A., CEO & Director (Age 60)
  • Dr. Manolo Bellotto Ph.D., Pres & GM (Age 50)
  • Mr. Salvatore Calabrese, Chief Financial Officer (Age 51)
  • Mr. Xavier Barril, Chief Scientific Officer
  • Dr. Ana Maria Garcia-Collazo Ph.D., Head of Research
  • Dr. Elena Cubero-Jorda Ph.D., Head of Computational Modeling
  • Dr. Natalia Perez-Carmona Ph.D., Head of Biology
  • Mr. Roberto Maj Pharm.D., Head of Devel.

Who are some of Gain Therapeutics' key competitors?

When did Gain Therapeutics IPO?

(GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

What is Gain Therapeutics' stock symbol?

Gain Therapeutics trades on the NASDAQ under the ticker symbol "GANX."

When does the company's quiet period expire?

Gain Therapeutics' quiet period expires on Tuesday, April 27th. Gain Therapeutics had issued 3,636,364 shares in its public offering on March 18th. The total size of the offering was $40,000,004 based on an initial share price of $11.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of Gain Therapeutics?

Shares of GANX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gain Therapeutics' stock price today?

One share of GANX stock can currently be purchased for approximately $13.20.

How much money does Gain Therapeutics make?

Gain Therapeutics has a market capitalization of $149.57 million.

What is Gain Therapeutics' official website?

The official website for Gain Therapeutics is www.gaintherapeutics.com.

How can I contact Gain Therapeutics?

The company can be reached via phone at 301-500-1556.


This page was last updated on 4/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.